Literature DB >> 2823969

alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates.

J M Palacios1, D Hoyer, R Cortés.   

Abstract

We have used membrane binding assays and in vitro autoradiographic techniques to study the characteristics and distribution of alpha 1-adrenoceptors in the brain of the rat, mouse, guinea pig, cat, pig, monkey and man. 125I-BE 2254 was used as ligand. The binding characteristics of alpha 1-adrenoceptors in the cortex of the rat and pig and the human cortex and hippocampus were fully comparable as shown by the binding profile of a series of alpha 1-adrenergic compounds. Differences were, however, seen in the densities of sites in human and rat hippocampus. Contrasting with the similarities seen in the pharmacological characteristics of alpha 1-adrenoceptors in the brain of several mammals, autoradiographic results showed dramatic differences in the regional distribution of brain alpha 1-adrenoceptors. While the thalamus and cortex were rich in alpha 1-sites in all the species investigated, differences in the nuclear and laminar distributions were seen between rodents and primates. One of the most important differences was the high density of alpha 1-adrenoceptors in the human and monkey hippocampus, mainly in the CA3, CA4 and dentate gyrus, while in all the other species investigated, the hippocampal formation was poor in these sites. These results suggest that, while alpha 1-adrenoceptors appear to be similar in their pharmacology, their distribution differs among these 6 mammals. Thus, different patterns of central activity can be expected from alpha 1-adrenergic drugs in the rodent and in the primate and man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823969     DOI: 10.1016/0006-8993(87)90569-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission.

Authors:  Yukio Ago; Ryota Araki; Koji Yano; Naoki Hiramatsu; Toshiyuki Kawasaki; Shigeyuki Chaki; Atsuro Nakazato; Hirotaka Onoe; Hitoshi Hashimoto; Akemichi Baba; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

Review 4.  Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 5.  Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.

Authors:  A Monro
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

6.  Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.

Authors:  J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango
Journal:  Brain Res       Date:  2013-02-27       Impact factor: 3.252

7.  Noradrenaline induces IPSCs in rat medial septal/diagonal band neurons: involvement of septohippocampal GABAergic neurons.

Authors:  M Alreja; W Liu
Journal:  J Physiol       Date:  1996-07-01       Impact factor: 5.182

8.  Neuroplasticity regulation by noradrenaline in mammalian brain.

Authors:  Aude Marzo; Jing Bai; Satoru Otani
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

9.  Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex.

Authors:  Satoshi Yamamura; Keiko Ohoyama; Tatsuya Hamaguchi; Kanae Kashimoto; Masanori Nakagawa; Shinichi Kanehara; Dai Suzuki; Takuya Matsumoto; Eishi Motomura; Takashi Shiroyama; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2009-07-03       Impact factor: 4.530

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.